The cluster of open-market sales by the CEO, a director, and the General Counsel following derivative exercises suggests a coordinated liquidity event rather than a panic, but the absence of 10b5-1 plan disclosures and the director's large $720K sale warrant monitoring. Watch for any upcoming corporate events (e.g., clinical data readouts, partnership announcements) that may have prompted the selling, and check for any subsequent Form 4 filings that disclose a trading plan.
Price Chart
Executive Summary
Three CRISPR Therapeutics insiders, including the CEO and General Counsel, sold a total of ~$973K in open-market sales on October 14, 2026, following derivative exercises on October 13. The CEO's sale of $202K and the director's sale of $720K represent a cluster of selling that is notable in absolute dollar terms but modest relative to the company's market cap. The sales are not clearly plan-driven and follow option exercises, raising a mild caution flag for near-term sentiment.
Key Financial Metrics
Key Facts
- CEO Samarth Kulkarni sold 4,098 shares for ~$202K on October 14, 2026.
- Director George Simeon sold 14,500 shares for ~$720K on October 14, 2026.
- General Counsel James R. Kasinger sold 1,040 shares for ~$51K on October 14, 2026.
- All three insiders exercised derivative securities (non-cash) on October 13, 2026, prior to the sales.
- Total open-market sales: ~$973K.
- No 10b5-1 plan indication was provided for any of the sales.
Financial Impact
Total insider sales of ~$973K, representing approximately 0.3% of the company's market cap (assuming ~$3.2B market cap based on ~65M shares at ~$49).
Risk Factors
- Insider selling cluster may signal lack of confidence in near-term catalysts or valuation.
- Director's $720K sale is the largest and most notable — could indicate a personal liquidity need or a bearish view.
- No 10b5-1 plan disclosed increases the likelihood of discretionary, potentially informed selling.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CRSP-1792532130985 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Insider Cluster | $50.50 | awaiting T+20 | — | $49.01 (+2.95%) |
Oct 19, 2026 7d ago | 8-K | $49.88 | awaiting T+20 | — | $49.01 (−1.74%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (−2.06%) |
Oct 16, 2026 10d ago | Insider Cluster | $50.04 | awaiting T+20 | — | $49.01 (+2.06%) |
Oct 15, 2026 11d ago | Insider Cluster | $49.25 | awaiting T+20 | — | $49.01 (−0.49%) |
Oct 14, 2026 12d ago | 144 | $51.52 | awaiting T+20 | — | $49.01 (−4.87%) |
Oct 6, 2026 20d ago | 144 | $52.35 | awaiting T+20 | — | $49.01 (−6.38%) |
Sep 24, 2026 4w ago | Insider Cluster | $54.23 $49.39 | ▲ +8.92% | ▲ +7.45% | $49.01 (+9.63%) |
Aug 28, 2026 8w ago | Press Release | $57.72 $54.23 | ▼ −6.05% | ▼ −6.56% | $49.01 (−15.09%) |
Aug 3, 2026 12w ago | Press Release | $53.07 $56.82 | ▲ +7.07% | ▲ +8.30% | $49.01 (−7.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers